Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer Recurrent|HER2/Neu-negative Carcinoma of Breast|Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: DRUG: Bevacizumab|DRUG: Capecitabine|DRUG: Everolimus|DRUG: Exemestane|OTHER: Patient questionaires
Sponsor: iOMEDICO AG
Collaborators: Arbeitsgemeinschaft fur Internistische Onkologie|Novartis Pharmaceuticals